Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/793
Title: | Programmed cell death-1 inhibition in lymphoma. |
Authors: | Hawkes, Eliza A. Grigg, Andrew Chong, Geoffrey |
Issue Date: | 2015 |
Publisher: | Elsevier |
Place of publication: | Philadelphia, PA |
Publication Title: | The Lancet Oncology |
Volume: | 16 |
Start Page: | e234 |
End Page: | e245 |
Abstract: | Cancers can evade the host immune system by inducing upregulation of immune inhibitory signals. Anti-programmed cell death-1 (PD-1) monoclonal antibodies block these inhibitory signals allowing the host to mount an immune response against malignant cells. This class of drugs is active in solid tumours, where upregulation of cell-surface PD-1 ligand proteins is nearly uniform. Because lymphoma is a malignancy of immune system cells, the role of the PD-1 pathway in these neoplasms is more complex. However, early clinical trials using PD-1 inhibitors have shown significant clinical activity in various subtypes of relapsed lymphoma. In this Review, we assess the scientific literature on the role of the PD-1 pathway in lymphoma, the relevant clinical data for PD-1 inhibition, and future strategies for this next generation of anticancer agents. |
URI: | http://hdl.handle.net/11054/793 |
Resource Link: | http://www.sciencedirect.com/science/article/pii/S1470204515701038 |
ISSN: | 1470-2045 |
Internal ID Number: | 00777 |
Health Subject: | CELL DEATH IMMUNE SYSTEM LYMPHOMA NEOPLASMS PROGRAMMED CELL DEATH 1 RECEPTOR |
Type: | Journal Article Article |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.